Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib in elderly unfit/frail mantle cell lymphoma
NCT07207785Phase 2Not yet recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression Free Survival at 48 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07207785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07207785.